The addition of nivolumab to rucaparib maintenance therapy did not improve progression-free survival (PFS) in patients with ovarian cancer, outcomes of the phase 3 ATHENA-COMBO trial demonstrated. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback